JP2010502767A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502767A5
JP2010502767A5 JP2009538434A JP2009538434A JP2010502767A5 JP 2010502767 A5 JP2010502767 A5 JP 2010502767A5 JP 2009538434 A JP2009538434 A JP 2009538434A JP 2009538434 A JP2009538434 A JP 2009538434A JP 2010502767 A5 JP2010502767 A5 JP 2010502767A5
Authority
JP
Japan
Prior art keywords
salt
compound
medicament
compound according
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009538434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502767A (ja
JP5161237B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078103 external-priority patent/WO2008033798A2/en
Publication of JP2010502767A publication Critical patent/JP2010502767A/ja
Publication of JP2010502767A5 publication Critical patent/JP2010502767A5/ja
Application granted granted Critical
Publication of JP5161237B2 publication Critical patent/JP5161237B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009538434A 2006-09-11 2007-09-11 Sykキナーゼ阻害剤としてのピロロピラジン Expired - Fee Related JP5161237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11
US60/825,168 2006-09-11
PCT/US2007/078103 WO2008033798A2 (en) 2006-09-11 2007-09-11 A pyrrolopyrazin as syk-kinase inhibitor

Publications (3)

Publication Number Publication Date
JP2010502767A JP2010502767A (ja) 2010-01-28
JP2010502767A5 true JP2010502767A5 (https=) 2010-10-07
JP5161237B2 JP5161237B2 (ja) 2013-03-13

Family

ID=39032357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538434A Expired - Fee Related JP5161237B2 (ja) 2006-09-11 2007-09-11 Sykキナーゼ阻害剤としてのピロロピラジン

Country Status (32)

Country Link
US (2) US8658649B2 (https=)
EP (1) EP2094708B1 (https=)
JP (1) JP5161237B2 (https=)
KR (1) KR101443056B1 (https=)
CN (2) CN103804383A (https=)
AR (1) AR062745A1 (https=)
AU (1) AU2007296592B8 (https=)
BR (1) BRPI0716781A2 (https=)
CA (1) CA2663175C (https=)
CL (1) CL2007002617A1 (https=)
CO (1) CO6160236A2 (https=)
CR (1) CR10636A (https=)
DK (1) DK2094708T3 (https=)
ES (1) ES2437318T3 (https=)
GT (1) GT200900055A (https=)
HN (1) HN2009000455A (https=)
IL (1) IL197381A (https=)
MA (1) MA30781B1 (https=)
MX (1) MX2009002616A (https=)
MY (1) MY148107A (https=)
NI (1) NI200900021A (https=)
NO (1) NO20091265L (https=)
NZ (1) NZ575496A (https=)
PE (1) PE20081372A1 (https=)
PT (1) PT2094708E (https=)
RU (1) RU2440352C2 (https=)
TN (2) TN2009000050A1 (https=)
TW (1) TWI399379B (https=)
UA (1) UA94622C2 (https=)
UY (1) UY30584A1 (https=)
WO (1) WO2008033798A2 (https=)
ZA (1) ZA200901073B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009218609A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
ATE522534T1 (de) * 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
CA2716223A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ.ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
MX2010008308A (es) * 2008-03-10 2010-08-11 Sanofi Aventis Tratamiento para trastornos relacionados con los ojos.
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es) 2008-12-03 2010-07-27 Sanofi Aventis Tratamiento para la glomerulonefritis
EP2373655A1 (en) 2008-12-04 2011-10-12 Sanofi Crystalline forms
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CA2799904A1 (en) * 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
CN102906095A (zh) 2010-05-20 2013-01-30 弗·哈夫曼-拉罗切有限公司 作为syk和jak抑制剂的吡咯并吡嗪衍生物
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換6−アザ−イソインドリン−1−オン誘導体
CN104507945B (zh) * 2012-08-21 2018-03-23 霍夫曼-拉罗奇有限公司 作为syk抑制剂的吡咯并[2,3‑b]吡嗪
NZ715747A (en) 2013-07-31 2017-03-31 Gilead Sciences Inc Syk inhibitors
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
DK0970084T3 (da) 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
AU7132998A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
ID24300A (id) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
ES2221213T3 (es) 1997-10-20 2004-12-16 F. Hoffmann-La Roche Ag Inhibidores de kinasa biciclicos.
WO1999045016A2 (en) 1998-03-06 1999-09-10 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
WO1999051233A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1070064A1 (en) 1998-04-02 2001-01-24 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ATE482945T1 (de) 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
CA2344262A1 (en) 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
AU2001247589A1 (en) 2000-03-20 2001-10-03 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en) 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
JP2004503553A (ja) 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 6,5−縮合二環式複素環
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
MX2007001126A (es) * 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
AU2005304952B2 (en) 2004-11-08 2013-04-04 Baxter Healthcare S.A. Nanoparticulate compositions of tubulin inhibitors
EP1814883A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
US20110112101A1 (en) 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Similar Documents

Publication Publication Date Title
JP2010502767A5 (https=)
CA2663175A1 (en) Kinase inhibitor
JP6194389B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
KR101663339B1 (ko) Raf 키나제의 억제를 위한 피롤로[2,3-b]피리딘 유도체
CN102480966B (zh) 融合的杂环化合物及其用途
JP2010526814A5 (https=)
JP2010515715A5 (https=)
JP2009516653A5 (https=)
JP2009502743A5 (https=)
JP7633178B2 (ja) ピロールアミド系化合物及びその用途
JP2010509356A5 (https=)
TW201706262A (zh) Dna烷化劑
JP2016503779A5 (https=)
JP2012526766A5 (https=)
JP2014065696A5 (https=)
JP2008518904A5 (https=)
TW201022281A (en) Imidazolothiazole compounds and methods of use thereof
JP2008513498A5 (https=)
JP2006514012A5 (https=)
TW201443043A (zh) 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
JP2009543843A (ja) 直接トロンビン阻害剤に関する新規適応
JP2009506014A5 (https=)
JP2010505961A5 (https=)
EA015103B1 (ru) Производные n-фенил-2-пиримидинамина и способ их получения
JP2012509265A5 (https=)